CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 48 enrolled
Drug / intervention
Lurasidonedrug
Likely dose
Lurasidone 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01423253
NCT01423253Phase 3Completed
CompareCT.gov

A 12-Week, Open-Label Extension Study For the Treatment of Major Depressive Disorder With Mixed Features

Sumitomo Pharma America, Inc.·interventional·Posted Aug 25, 2011·Updated Apr 8, 2016

In Brief

A Phase 3 clinical trial evaluating Lurasidone for Major Depressive Disorder. Completed, enrolled 48 participants across 17 sites.

Detailed Summary

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features over time.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 25, 2011
Enrollment StartSep 1, 2011
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.9 years ago

Interventions

Lurasidonedrug

Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed